BridgeBio Pharma, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
BridgeBio Pharma is a commercial-stage biopharmaceutical company developing medicines for genetically driven diseases and cancers through wholly owned and controlled subsidiaries. This report covers the three months ended March 31, 2024; amounts are in thousands unless otherwise stated.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $211.1 million | $1.8 million | +$209.3 million |
| Operating costs and expenses | $210.8 million | $128.0 million | +$82.8 million |
| Income (loss) from operations | $0.3 million | $(126.2) million | +$126.5 million |
| Net loss | $(36.2) million | $(142.7) million | Improved $106.6 million |
| Net loss attributable to common stockholders | $(35.2) million | $(140.2) million | Improved $104.9 million |
| Basic and diluted loss per share | $(0.20) | $(0.92) | Improved |
| Net cash used in operating activities | $(219.5) million | $(144.3) million | +$75.2 million use |
- Revenue included $130.5 million of license revenue under the Bayer agreement, $70.7 million under the Kyowa Kirin agreement, $9.9 million of remaining services revenue under the terminated Navire-BMS agreement, and approximately $1.6 million of Kyowa Kirin services revenue.
- Research and development expense was $141.0 million, up $48.1 million, driven by higher external and personnel costs, licensing fees, and stock-based compensation. Key program spending included acoramidis of $39.7 million, infigratinib of $18.4 million, encaleret of $12.5 million, and BBP-418 of $10.0 million.
- Selling, general and administrative expense was $65.8 million, up $34.7 million, primarily from $14.0 million of nonrecurring deal-related costs, higher personnel and commercialization-readiness costs, and stock-based compensation.
- Operating margin was approximately 0.2% in Q1 2024, compared with negative 6,906% in Q1 2023; the comparison is distorted by the large upfront license revenue recognized in 2024. Net margin was approximately negative 17.1% versus negative 7,815%.
- Cash, cash equivalents and marketable securities totaled $519.7 million at March 31, 2024, compared with $375.9 million of cash and cash equivalents at December 31, 2023. Restricted cash was $0.1 million, and cash, cash equivalents and restricted cash totaled $477.5 million.
- Operating cash outflow reflected a $233.7 million increase in licensing and collaboration receivables, including $135.0 million from Bayer and $100.0 million from Kyowa Kirin, before collection.
- Financing cash inflows included $450.0 million of new term-loan proceeds and $315.3 million of net equity issuance proceeds, partially offset by repayment of the prior term loan and related costs.
Debt and capital structure
- Outstanding debt was approximately $1.7 billion net of discounts, comprising $737.4 million of 2.25% convertible senior notes due 2029, $543.8 million of 2.50% convertible senior notes due 2027, and $434.7 million of the new term loan.
- On January 17, 2024, BridgeBio repaid the prior term loan for $475.8 million and recorded a $26.6 million loss on extinguishment of debt.
- The replacement senior secured facility has a $450.0 million initial term loan and up to $300.0 million of incremental capacity. Interest is based on a base rate plus 5.75% or Term SOFR plus 6.75%, subject to stated floors.
- The new facility requires a minimum qualified cash balance of $70.0 million, is secured by substantially all assets of the company and guarantors, and generally matures January 17, 2029, subject to springing earlier maturities tied to the convertible notes.
Material changes versus the prior comparable period
- Revenue increased substantially because of the Bayer and Kyowa Kirin license transactions; Q1 2023 revenue was primarily services revenue under the Navire-BMS arrangement.
- Net loss narrowed despite higher operating expenses, reflecting the license revenue and a $26.6 million debt-extinguishment charge in Q1 2024.
- BridgeBio issued 9.9 million shares in a March 2024 follow-on offering for net proceeds of approximately $276.6 million and issued 1.1 million shares under its ATM program for $38.1 million of net proceeds.
- Investing activities generated $22.8 million, including $63.2 million of proceeds from equity-security sales and $25.7 million of special cash dividends, partially offset by purchases of marketable and equity securities.
- The company’s equity investment balance declined from $58.9 million at December 31, 2023 to zero at March 31, 2024 after sales of LianBio-related securities and exercise of the LianBio warrant.
- BMS provided notice that it would terminate the Navire-BMS license agreement effective June 2024. BridgeBio recognized the remaining $9.9 million of services revenue in Q1 2024; future royalties under that agreement are no longer expected.
Guidance, outlook, risks and unusual items
- Management expects continued operating and net losses for at least the next several years and has not provided product-sales guidance.
- Management states that available cash, marketable securities, restricted cash and licensing receivables are expected to fund operations for at least the next 12 months based on current plans and forecasts. Additional financing may nevertheless be required sooner if plans or market conditions change.
- BridgeBio expects to receive $235.0 million from Bayer and Kyowa Kirin during Q2 2024. Under the new financing agreement, 75% of net proceeds from these asset-sale transactions must be deposited into an escrow account controlled by the administrative agent.
- The company entered into a funding agreement providing for up to $500.0 million upon the first FDA approval of acoramidis in exchange for a royalty interest initially equal to 5% of global net sales, potentially increasing to 10% in 2027. No proceeds had been received as of March 31, 2024, and the agreement may terminate without penalty if funding does not occur by May 15, 2025.
- Additional restructuring plans are expected to produce $12.0 million to $16.0 million of remaining charges, primarily for winding down, exit, severance and employee-related costs.
- Key risks include clinical and regulatory failure, uncertain market acceptance and reimbursement, dependence on third-party manufacturers and contract research organizations, intellectual-property disputes, financing needs, debt covenants and accelerated maturities, supply-chain and inflationary pressures, and the ability to commercialize product candidates.
- On April 30, 2024, BridgeBio completed a $200.0 million private financing with external investors in TheRas, Inc. to accelerate oncology development; the filing states that the financial impact was still being evaluated.
Most important facts for investors to verify
- Timing and collectability of the $135.0 million Bayer and $100.0 million Kyowa Kirin receivables and the related escrow restrictions.
- FDA and commercial progress for acoramidis, including the conditions and timing of the potential $500.0 million funding agreement.
- Cash-burn trajectory excluding one-time license proceeds, and the duration of liquidity after required escrow deposits and debt service.
- Interest-rate exposure and covenant compliance under the variable-rate $450.0 million secured term loan, including the $70.0 million minimum cash requirement.
- Magnitude and timing of the estimated $12.0 million to $16.0 million restructuring charges and the operational impact of the BMS termination.
- Upcoming obligations under the $550.0 million 2027 convertible notes and $747.5 million 2029 convertible notes, including potential conversion or repurchase requirements.
- Financial impact of the April 30, 2024 $200.0 million BBOT private financing and any resulting changes in ownership, consolidation or noncontrolling interests.